1.
Could you please clarify which types of products are eligible for priority review in Canada (p. 5-6)? In the US and Europe, some expedited review programs, like the US Food and Drug Administration's accelerated approval pathway, allow for substantial flexibility in evidence standards, similarly to the Notice of Compliance with conditions (NOC/c) pathway in Canada. It would be helpful if you could add a sentence justifying why priority review drugs were grouped under the standard approval pathway rather than the NOC/c pathway.
2.
If we accept the notion that greater uncertainty around the efficacy and safety of a non-oncology product seems to make panel members of the Common Drug Review less likely to recommend that the product be listed on Canadian public formularies, what can policymakers, regulators, physicians, pharmacists, and other health stakeholders in Canada and elsewhere learn from this? Why is this important evidence for the wider health policy audience? a.
Perhaps the author could give some policy recommendations and/or suggestions for future studies. You mention the potential use of risk-sharing arrangements, like coverage with evidence development and performance-based schemes, but it is not clear whether the author believes Canadian policymakers should pursue such arrangements. The author could cite recent studies, like Ferrario and Kanavos (2014) and Neumann et al. (2011) , to contextualize any suggestions.
3.
I appreciate that the author was careful not to overinterpret the study findings. There are a few instances, though, where I would tone down the language, since one is not able to draw any causal conclusions based on this research, as explained in the paper.
a.
Under the objectives in the abstract (p.2), I would write that the aim of the study was to "investigate if the recommendations by the …. are associated with the approval pathway …" (or something to that effect), instead of saying "… are influenced by …".
b.
Similarly, in the first sentence of the discussion (p. 10), I would write that "… there was no association between the approval pathway and the recommendation to list or not to list a product …", instead of saying that "… the approval pathway does not matter …".
4.
In the discussion section, I would highlight the need for follow-up studies to validate your findings, given the small sample sizes in some of the categories, notably NOC/c products. As you stated, the addition or elimination of a few products could change the significance of the results, so future studies could re-run your analyses once more recommendations have been published.
5.
A few minor suggestions: a.
In the results section, I would present the results for the full sample (p. 10, last paragraph) before showing the results for the oncology and non-oncology products separately. b.
In the discussion section, could you please add a sentence at the beginning of the penultimate paragraph (p. 12) to explain that you are listing the study limitations (e.g. "This study has several limitations."). I think this would improve the flow of the text. c.
I would suggest you remove all web addresses in the abstract, which make the "Data sources" section tedious to read. d.
Could you please add parentheses around the URL for the Summary Basis of Decision website (p. 8) to be consistent with the earlier parts of the sentence? e.
I would remove the word "combined" in the first sentence of the results (p. 8). f.
CADTH is a HTA agency, and CDR and pCODR are two review processes administered by CADTH (not "two health technology assessment agencies", p. 5). Could the author please change the text accordingly. 
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GENERAL COMMENTS
I understand the manuscript, but primary comments are in the Objective description (promise to review impact of CDR and pOCDR recommendations on provincial, etc., drug formularies. The recommendations are available for provincial formulary decision makers, but project does not measure this impact. Otherwise, no other comments. I understand the Discussion on performance based and CED approaches, but research seems to include clinical data and recommendations, but not economic, or value-based, evaluations and recommendations. If so, at least not clear. I understand CED can ignore economic outcomes, but a question of "value" seems to be a constant companion to decision makers. Finally, In addition to the interesting statistical correlations on "List/Do Not List" listing, but a good follow-on study is to measure the impact (acceptance) of listing recommendations on provincial, etc., drug formulary decisions. The reviewer also provided a marked copy with additional comments. Please contact the publisher for full details. Comment 1. Could you please clarify which types of products are eligible for priority review in Canada (p. 5-6)? In the US and Europe, some expedited review programs, like the US Food and Drug Administration's accelerated approval pathway, allow for substantial flexibility in evidence standards, similarly to the Notice of Compliance with conditions (NOC/c) pathway in Canada. It would be helpful if you could add a sentence justifying why priority review drugs were grouped under the standard approval pathway rather than the NOC/c pathway.
Response: The quote on page 6 is the information provided by Health Canada regarding what types of products are considered for approval under the NOC/c pathway.
Drugs approved under either the priority or standard pathway have to have completed all of the necessary studies and therefore have a complete set of evidence. Therefore, they are considered together.
Comment 2. If we accept the notion that greater uncertainty around the efficacy and safety of a non-oncology product seems to make panel members of the Common Drug Review less likely to recommend that the product be listed on Canadian public formularies, what can policymakers, regulators, physicians, pharmacists, and other health stakeholders in Canada and elsewhere learn from this? Why is this important evidence for the wider health policy audience?
Response: Perhaps the author could give some policy recommendations and/or suggestions for future studies. You mention the potential use of risk-sharing arrangements, like coverage with evidence development and performance based schemes, but it is not clear whether the author believes Canadian policymakers should pursue such arrangements. The author could cite recent studies, like Ferrario and Kanavos (2014) and Neumann et al. (2011) , to contextualize any suggestions.
The following final paragraph has been added to the manuscript: "In the face of similar concerns about prices and clinical effectiveness, in 2011 the Australian government and the industry association, Medicines Australia, introduced a framework agreement for an outcomes-based managed entry scheme (MES). Under a MES, the Australian health technology assessment agency, the Pharmaceutical Benefits Advisory Committee (PBAC), could recommend the listing of a new medicine with a high clinical need at a price justified by the existing evidence, pending the availability of more conclusive evidence of cost-effectiveness 20 21. Although not formally stated in the framework agreement, the expectation is that new evidence would be in the form of randomized clinical trials with hard clinical outcomes and that superiority trials will be more acceptable to the PBAC 21. Currently, CDR and pCODR can recommend not listing at the submitted price, but if the number of NOC/c approved products increase, Health Canada should consider expanding the mandate of the CDR and pCODR to include recommendations for listing drugs under a managed entry scheme modeled on the one used in Australia." I thank the reviewer for the suggestion of the references but since I am recommending a model introduced in Australia I have used two references to that model.
